RU2717887C1 - Приемник для приема данных об аналите и способ его работы - Google Patents
Приемник для приема данных об аналите и способ его работы Download PDFInfo
- Publication number
- RU2717887C1 RU2717887C1 RU2018137017A RU2018137017A RU2717887C1 RU 2717887 C1 RU2717887 C1 RU 2717887C1 RU 2018137017 A RU2018137017 A RU 2018137017A RU 2018137017 A RU2018137017 A RU 2018137017A RU 2717887 C1 RU2717887 C1 RU 2717887C1
- Authority
- RU
- Russia
- Prior art keywords
- analyte
- value
- values
- time interval
- receiver
- Prior art date
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 386
- 238000000034 method Methods 0.000 title claims abstract description 99
- 230000008859 change Effects 0.000 claims abstract description 99
- 238000005259 measurement Methods 0.000 claims description 38
- 230000008569 process Effects 0.000 claims description 33
- 238000012544 monitoring process Methods 0.000 claims description 18
- 238000004458 analytical method Methods 0.000 claims description 11
- 238000001514 detection method Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 62
- 239000008103 glucose Substances 0.000 description 62
- 230000005540 biological transmission Effects 0.000 description 35
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 238000012546 transfer Methods 0.000 description 14
- 230000002641 glycemic effect Effects 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 238000004891 communication Methods 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 238000005070 sampling Methods 0.000 description 8
- 230000001953 sensory effect Effects 0.000 description 8
- 230000001133 acceleration Effects 0.000 description 6
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 238000004422 calculation algorithm Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 208000013016 Hypoglycemia Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 230000037081 physical activity Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000013213 extrapolation Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 230000005236 sound signal Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient; User input means
- A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01Q—ANTENNAS, i.e. RADIO AERIALS
- H01Q1/00—Details of, or arrangements associated with, antennas
- H01Q1/27—Adaptation for use in or on movable bodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Optics & Photonics (AREA)
- Artificial Intelligence (AREA)
- Signal Processing (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16162661.9 | 2016-03-29 | ||
| EP16162661 | 2016-03-29 | ||
| EP17163229 | 2017-03-28 | ||
| EP17163229.2 | 2017-03-28 | ||
| PCT/EP2017/057437 WO2017167815A1 (en) | 2016-03-29 | 2017-03-29 | Method of operating a receiver for receiving analyte data, receiver and computer program product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2717887C1 true RU2717887C1 (ru) | 2020-03-26 |
Family
ID=58464532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018137017A RU2717887C1 (ru) | 2016-03-29 | 2017-03-29 | Приемник для приема данных об аналите и способ его работы |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11369319B2 (https=) |
| EP (1) | EP3435865B1 (https=) |
| JP (1) | JP7088840B2 (https=) |
| CN (1) | CN108882893A (https=) |
| CA (1) | CA3018351C (https=) |
| ES (1) | ES2998028T3 (https=) |
| IL (1) | IL261594B (https=) |
| PL (1) | PL3435865T3 (https=) |
| RU (1) | RU2717887C1 (https=) |
| WO (1) | WO2017167815A1 (https=) |
| ZA (1) | ZA201806205B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102372113B1 (ko) | 2016-10-05 | 2022-03-07 | 에프. 호프만-라 로슈 아게 | 다중 분석물 진단 테스트 엘리먼트들을 위한 검출 시약들 및 전극 배열들, 그리고 그것을 사용하는 방법들 |
| EP3788628B1 (en) * | 2018-05-04 | 2024-12-11 | Insulet Corporation | Safety constraints for a control algorithm-based drug delivery system |
| KR102737255B1 (ko) * | 2019-03-19 | 2024-12-03 | 삼성전자주식회사 | 전자 장치 및 전자 장치에서의 생체 정보 알림 방법 |
| WO2022186360A1 (ja) * | 2021-03-05 | 2022-09-09 | 富士フイルム株式会社 | 情報処理装置、情報処理システム、情報処理方法及び情報処理プログラム |
| US12496398B2 (en) * | 2021-05-28 | 2025-12-16 | Insulet Corporation | Threshold based automatic glucose control response |
| FR3125696A1 (fr) * | 2021-07-27 | 2023-02-03 | Pkvitality | Gestion des alertes dans un procédé de détection de la concentration d’un analyte contenu dans un fluide corporel d’un individu |
| EP4415617A1 (en) * | 2021-10-14 | 2024-08-21 | Biolinq Incorporated | Interoperability and data exchange capabilities between a blood glucose monitor and a continuous glucose monitor |
| WO2025229048A1 (en) | 2024-05-02 | 2025-11-06 | Roche Diabetes Care Gmbh | Methods and devices for controlling an analyte sensor device |
| WO2026073090A1 (en) * | 2024-09-30 | 2026-04-02 | Dexcom, Inc. | Dynamically adapting analyte rate-of-change determination to a current patient context |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090118592A1 (en) * | 2005-12-08 | 2009-05-07 | Novo Nordisk A/S | Medical System Comprising a Sensor Device |
| US20110077494A1 (en) * | 2009-09-29 | 2011-03-31 | Abbott Diabetes Care Inc. | Method and Apparatus for Providing Notification Function in Analyte Monitoring Systems |
| US20120065482A1 (en) * | 2005-04-08 | 2012-03-15 | Mark Ries Robinson | Determination of blood pump system performance and sample dilution using a property of fluid being transported |
| US20140148659A1 (en) * | 2012-11-29 | 2014-05-29 | Abbott Diabetes Care Inc. | Methods, Devices, and Systems Related to Analyte Monitoring |
| US20150216457A1 (en) * | 2014-01-31 | 2015-08-06 | Seiko Epson Corporation | Blood glucose level measurement apparatus and blood glucose level measurement method |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6505059B1 (en) | 1998-04-06 | 2003-01-07 | The General Hospital Corporation | Non-invasive tissue glucose level monitoring |
| US6648821B2 (en) | 2000-01-21 | 2003-11-18 | Medtronic Minimed, Inc. | Microprocessor controlled ambulatory medical apparatus with hand held communication device |
| CA2400309A1 (en) * | 2000-02-18 | 2001-08-23 | Argose,Inc. | Non-invasive tissue glucose level monitoring |
| CA2649563C (en) | 2006-04-20 | 2015-02-17 | Manfred Ebner | Method for transmitting data in a blood glucose system and corresponding blood glucose system |
| WO2008057384A2 (en) | 2006-11-02 | 2008-05-15 | The University Of North Carolina At Chapel Hill | Methods and systems for determining an intravenous insulin infusion rate |
| JP2008253438A (ja) * | 2007-04-03 | 2008-10-23 | Matsushita Electric Ind Co Ltd | 非侵襲生体情報測定装置 |
| US20090126859A1 (en) | 2007-11-16 | 2009-05-21 | Cadwallader Robert J | Process for producing glass laminates |
| US8822903B2 (en) | 2008-09-23 | 2014-09-02 | Nxp, B.V. | Detection system for the detection of movements of a movable object, a method of detecting movements of a movable object, and an IC having implemented therein the detection system |
| US20100198034A1 (en) | 2009-02-03 | 2010-08-05 | Abbott Diabetes Care Inc. | Compact On-Body Physiological Monitoring Devices and Methods Thereof |
| US8562587B2 (en) | 2009-02-25 | 2013-10-22 | University Of Virginia Patent Foundation | CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery |
| EP4070728A1 (en) | 2009-08-31 | 2022-10-12 | Abbott Diabetes Care, Inc. | Displays for a medical device |
| EP2473963A4 (en) * | 2009-08-31 | 2014-01-08 | Abbott Diabetes Care Inc | MEDICAL DEVICES AND METHOD |
| DK3622883T3 (da) | 2010-03-24 | 2021-07-19 | Abbott Diabetes Care Inc | Indførerer til medicinsk indretning og fremgangsmåder til at indføre og anvende medicinske indretninger |
| RU2602040C2 (ru) | 2011-08-26 | 2016-11-10 | Университи Оф Вирджиния Патент Фоундэйшион | Способ, система и машиночитаемый носитель для адаптационного рекомендательного контроля сахарного диабета |
| WO2013046911A1 (ja) * | 2011-09-27 | 2013-04-04 | テルモ株式会社 | アナライトモニタシステム |
| JP6046116B2 (ja) * | 2012-03-27 | 2016-12-14 | テルモ株式会社 | アナライトのモニタシステム及びモニタ方法 |
| US10391242B2 (en) * | 2012-06-07 | 2019-08-27 | Medtronic Minimed, Inc. | Diabetes therapy management system for recommending bolus calculator adjustments |
| NZ740700A (en) | 2012-07-27 | 2019-07-26 | Aragon Pharmaceuticals Inc | Methods and compositions for determining resistance to androgen receptor therapy |
| CN104755025A (zh) | 2012-08-29 | 2015-07-01 | 悉尼科技大学 | 用于识别高血糖的方法和设备 |
| US10149617B2 (en) | 2013-03-15 | 2018-12-11 | i4c Innovations Inc. | Multiple sensors for monitoring health and wellness of an animal |
| CN116170766A (zh) | 2013-11-07 | 2023-05-26 | 德克斯康公司 | 用于分析物值的发射和连续监测的系统和方法 |
| EP4309570A1 (en) | 2013-12-16 | 2024-01-24 | DexCom, Inc. | Systems and methods for monitoring and managing life of a battery in an analyte sensor system worn by a user |
| JP6566241B2 (ja) * | 2014-06-25 | 2019-08-28 | パナソニックＩｐマネジメント株式会社 | 健康管理システム、健康管理装置及び表示方法 |
-
2017
- 2017-03-29 WO PCT/EP2017/057437 patent/WO2017167815A1/en not_active Ceased
- 2017-03-29 US US16/088,307 patent/US11369319B2/en active Active
- 2017-03-29 CA CA3018351A patent/CA3018351C/en active Active
- 2017-03-29 CN CN201780021058.6A patent/CN108882893A/zh active Pending
- 2017-03-29 IL IL261594A patent/IL261594B/en unknown
- 2017-03-29 PL PL17715091.9T patent/PL3435865T3/pl unknown
- 2017-03-29 EP EP17715091.9A patent/EP3435865B1/en active Active
- 2017-03-29 RU RU2018137017A patent/RU2717887C1/ru active
- 2017-03-29 JP JP2018551242A patent/JP7088840B2/ja active Active
- 2017-03-29 ES ES17715091T patent/ES2998028T3/es active Active
-
2018
- 2018-09-14 ZA ZA2018/06205A patent/ZA201806205B/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120065482A1 (en) * | 2005-04-08 | 2012-03-15 | Mark Ries Robinson | Determination of blood pump system performance and sample dilution using a property of fluid being transported |
| US20090118592A1 (en) * | 2005-12-08 | 2009-05-07 | Novo Nordisk A/S | Medical System Comprising a Sensor Device |
| US20110077494A1 (en) * | 2009-09-29 | 2011-03-31 | Abbott Diabetes Care Inc. | Method and Apparatus for Providing Notification Function in Analyte Monitoring Systems |
| US20140148659A1 (en) * | 2012-11-29 | 2014-05-29 | Abbott Diabetes Care Inc. | Methods, Devices, and Systems Related to Analyte Monitoring |
| US20150216457A1 (en) * | 2014-01-31 | 2015-08-06 | Seiko Epson Corporation | Blood glucose level measurement apparatus and blood glucose level measurement method |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3435865C0 (en) | 2024-10-23 |
| ES2998028T3 (en) | 2025-02-18 |
| CA3018351C (en) | 2024-02-13 |
| CA3018351A1 (en) | 2017-10-05 |
| PL3435865T3 (pl) | 2025-03-24 |
| JP2019512347A (ja) | 2019-05-16 |
| ZA201806205B (en) | 2019-07-31 |
| CN108882893A (zh) | 2018-11-23 |
| US11369319B2 (en) | 2022-06-28 |
| BR112018068937A8 (pt) | 2023-03-07 |
| JP7088840B2 (ja) | 2022-06-21 |
| EP3435865B1 (en) | 2024-10-23 |
| IL261594A (en) | 2018-10-31 |
| US20200281538A1 (en) | 2020-09-10 |
| BR112018068937A2 (pt) | 2019-01-22 |
| IL261594B (en) | 2022-08-01 |
| EP3435865A1 (en) | 2019-02-06 |
| WO2017167815A1 (en) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2717887C1 (ru) | Приемник для приема данных об аналите и способ его работы | |
| AU2024201688B2 (en) | System and method for decision support | |
| CN115177241B (zh) | 用于提供针对用户优化的告警的系统和方法 | |
| US11553883B2 (en) | System, device and method of dynamic glucose profile response to physiological parameters | |
| US20230343430A1 (en) | Medicament adaptation and safety monitoring | |
| HK1260051A1 (en) | Method of operating a receiver for receiving analyte data, receiver and computer program product | |
| EP4679442A1 (en) | Methods to modify behaviors to mitigate impact of prediction inaccuracies for later time windows in amd systems | |
| US20250302381A1 (en) | Use of a variability metric of glucose level values to identify a sleeping time frame for a user of a medicament delivery device | |
| US20240225535A1 (en) | Systems, devices, and methods relating to medication dose guidance | |
| US20220249773A1 (en) | Techniques and devices for adaptation of maximum drug delivery limits | |
| US20260007824A1 (en) | Methods to rapidly assess changes in medicament needs for accelerated short-term adaptivity of automated medicament delivery systems | |
| CN121926590A (zh) | 用于提供针对用户优化的告警的系统和方法 |